Exhibitors Search
UCI Therapeutics inc.
|
Exhibition
|
|
|---|---|
|
Booth no.
|
E41 |
|
Country
|
Korea, South |
|
Address
|
87 Cheongam-ro, Nam-gu, Pohang-si, Gyeongsangbuk-do, Republic of Korea |
|
Tel
|
<031-522-5315 |
|
Exhibits
|
종양 미세환경 제어 및 이중 표적 기능이 강화된 차세대 CAR-NK 면역 세포치료제 |
|
Company Type
|
Exhibitor Information
UCI Therapeutics is an innovative biotech company focused on developing next-generation anti-cancer immune cell therapies, particularly CAR-NK (Chimeric Antigen Receptor-Natural Killer cell) therapies. Overcoming the limitations of existing immuno-oncology drugs, it presents new possibilities for treating recurrent and refractory cancers, accelerating commercialization based on robust R&D capabilities. Specifically, through its differentiated approaches of ‘dual-specificity antibodies’ and ‘tumor microenvironment modulation,’ it provides a new treatment option that is safe and offers reduced treatment cost burdens.
Exhibit/Technology Introduction (General)
Next-generation CAR-NK immunotherapy with enhanced tumor microenvironment control and dual-target functionality
Individual Exhibit/Technology Introduction (Detailed)
-
Product Name : Next-generation CAR-NK immunotherapy with enhanced tumor microenvironment control and dual-target functionalityThis technology is a next-generation immunotherapy agent, specifically an allogenic, off-the-shelf CAR-NK cell therapy developed through genetic engineering. It targets blood cancers with a “bi-specific CAR-NK” approach, simultaneously secreting both cancer-targeted CARs and TME-modulating peptides.
KYUNGYON EXHIBITION CORP.